Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients

VU University medical center0 个研究点目标入组 225 人开始时间: 2012年5月9日最近更新: 2012年6月26日

试验速览

暂无简介。

•Patients with advanced (unresectable and/or metastatic) renal cell cancer.
•Patients who will start treatment with sunitinib, pazopanib, sorafenib, axitinib or everolimus.
•At least one tumor lesion should be accessible for biopsy. Bone metastases are excluded as possible biopsy site.
•Age > 18 years.
•Patients must have at least one measurable lesion. Lesions must be evaluated by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).
•WHO performance status 0 - 2
•Able to provide written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 180
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 45

•Clinical findings associated with an unacceptably high tumor biopsy risk, according to the judgement of the investigator.
•Radiotherapy on target lesions during study or within 4 weeks of the start of study drug.
•Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study.

发起方

VU University medical center